IL-12B Polyclonal Antibody

货号：ES5895
价格：面议
点击：2598

产品介绍

抗体信息

应用	WB;ELISA
反应种属	Human;Rat;Mouse;
别称	IL12B; NKSF2; Interleukin-12 subunit beta; IL-12B; Cytotoxic lymphocyte maturation factor 40 kDa subunit; CLMF p40; IL-12 subunit p40; NK cell stimulatory factor chain 2; NKSF2

【仅供科学研究使用】

相关产品:

产品名称	点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody \|抗卡瑞利珠单抗中和重组抗体(靶标：卡瑞利珠单抗中和抗体)	499
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	274
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	472
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	230
Anti-Golimumab Neutralizing Recombinant Antibody \|抗戈利木单抗中和重组抗体(靶标：戈利木单抗中和抗体)	346
Anti-Infliximab Non-Neutralizing Recombinant Antibody \|抗英夫利昔单抗非中和重组抗体(靶标：英夫利昔单抗非中和抗体)	482
Anti-Infliximab Non-Neutralizing Recombinant Antibody \|抗英夫利昔单抗非中和重组抗体(靶标：英夫利昔单抗非中和抗体)	436
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	522
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	388
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	172
Anti-Infliximab Neutralizing Recombinant Antibody \|抗英夫利昔单抗中和重组抗体(靶标：英夫利昔单抗中和抗体)	338
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	256
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	516
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	410
Anti-Matuzumab Neutralizing Recombinant Antibody \|抗马妥珠单抗中和重组抗体(靶标：马妥珠单抗中和抗体)	374
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody\|抗埃罗妥珠单抗非中和重组抗体(靶标：埃罗妥珠单抗非中和抗体)	517
Anti-Elotuzumab Neutralizing Recombinant Antibody \|抗埃罗妥珠单抗中和重组抗体(靶标：埃罗妥珠单抗中和抗体)	176
Anti-Elotuzumab Neutralizing Recombinant Antibody \|抗埃罗妥珠单抗中和重组抗体(靶标：埃罗妥珠单抗中和抗体)	259
Anti-Oleclumab Neutralizing Recombinant Antibody \|抗奥乐克单抗中和重组抗体(靶标：奥乐克单抗中和抗体)	240
Anti-Oleclumab Neutralizing Recombinant Antibody \|抗奥乐克单抗中和重组抗体(靶标：奥乐克单抗中和抗体)	238

在线客服

QQ交谈

销售热线：
15898894496(同微信)
我要留言
周一至周五每天9:00-17:00